There are more molecules that could conceivably be candidate drugs than there are stars in the universe. How can we ever efficiently identify those molecules? Professor of AI and Medicinal Chemistry, Gerard van Westen: ‘I’m going to use artificial intelligence as the co-pilot to make an automated search.’…

Developing new drugs is a difficult process. With the aid of artificial intelligence, Pharmaceutical scientist Xuhan Liu has developed methods that can help make drug design cheaper and faster. PhD defence on 15 February.

Why does a medicine work well for one person, but cause side effects in another? Research by Laura de Jong shows that it’s not just our DNA that matters – other medicines and illnesses can also affect how our bodies respond.

Oncode Investigator Mario van der Stelt and his colleagues have discovered a new potential drug that suppresses chemotherapy induced neuropathic pain.

His article on ‘the War on Drugs’ in Colombia and the Philippines has been in the top five most downloaded articles of Oxford University Press for some time. Now, Assistant Professor Santino Regilme is to receive a NIAS grant to map out the global war on drugs.

Psychedelic drugs like magic mushrooms and LSD are embraced by some and seen as lethal by others. Cognitive psychologist Michiel van Elk delved into the world of psychedelic drugs and wrote a surprisingly sober book about them. ‘Without first-hand experience my story wouldn’t be complete.’

Recently, we had the LACDR PhD Introductory course on Drug Research for starting PhD candidates. It was great to have this live event live in castle Oud Poelgeest, after two years of restrictions.

Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process.

At the end of February, we had the PhD Introductory Course on Drug Research for starting PhD candidates from LACDR. This 3-days event took place at Castle Oud Poelgeest, a great location to be completely out of the work environment. We welcomed 30 PhD candidates, with whom we had an inspiring and…

This week, we had the LACDR PhD Introductory course on Drug. This is always a great opportunity for starting PhD candidates to get to know LACDR, CHDR, the Clinical Pharmacology department of LUMC and the embedding of the institute in the BioSciencepark as a whole.

Due to the great influx of PhD candidates, we had the pleasure to organize a 2nd PhD Introductory Course on Drug research this year. From November 4- 6, we welcomed 30 participants for this 3-days event, which took place at Castle Oud Poelgeest.

Due to the corona pandemic and the uncertainty of the circumstances end of January 2022, is decided to postpone the LACDR PhD introductory course.

The PhD introductory course will take place on 30 May, 31 May and 1 June 2022 in castle Oud Poelgeest. We are very happy that it will be a live event (as it stands now).

Bringing your drug candidates to patients is what many academic chemists dream about, but the road to this goal is long and bumpy. Now, Leiden small molecule nizubaglustat is ready for phase 3 clinical trials. This is thanks to a €132 million funding secured by the biotech spin-out Azafaros.

Cancer research generates massive amounts of data, but traditional tools often fail to fully harness their potential. How can we unlock this data to provide better treatments for cancer patients? PhD candidate Marina Gorostiola González explored this by using advanced data analysis techniques to guide…

Willem Jespers started his position as Assistant Professor in the group of Prof. G.J.P. van Westen on June 1st, a short introduction below:

Nerve pain is one of the most common side effects of chemotherapy. It is therefore one of the biggest reasons for cancer patients to stop treatment early. Darcy Reynolds worked on new drug candidates against this pain during her bachelor's thesis. She developed a new series of molecules that increase…

Chemist Tobias Bauer discovered ways to improve drugs by encapsulating them. Packages with iron nanoparticles, for example, can stimulate immune cells. Bauer will receive his PhD on 9 June.

PhD candidate Mengxu Zhang (Division of Systems Pharmacology and Pharmacy) published a comprehensive and important review on “The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure” in Drug Metabolism Reviews.

Marieke Liem, professor at ISGA, discusses how the number of drug-related murders has not decreased in the last years

Drug use during pregnancy seems like a choice without any consequences. However, the Dutch Public Prosecution Service (OM) has decided to prosecute a mother for using alcohol and drugs during her pregnancy. Mariëlle Bruning, Professor of Child Law, tells current affairs programme ‘Nieuwsuur’ that she…

On 14 April, the National Growth Fund awarded million euros in grants to two consortia in which Leiden's science faculty is involved. Pharma-NL will receive 80 million euros and Oncode-PACT 325 million euros. Pharma-NL wants to make medicines available to the patient faster and more sustainably. Oncode-PACT…

Polypeptide Therapeutic Solutions (PTS), a leader in the design, development and custom manufacturing of polyamino-acid based delivery systems for therapeutic drugs and the Leiden Academic Centre for Drug Research (LACDR) today announced a research collaboration to develop advanced drug delivery systems…

One discovered that arteriosclerosis resembles an autoimmune disease, while the other developed a system to aid in the search for new medications. For these achievements, Marie Depuydt and Jurren de Groot were awarded the Krijn Rietveld Memorial Innovation Award on the evening of Tuesday 4 June.

In prehistoric times there was a huge wave of migration, from the steppes in Russia and Ukraine to West Europe. The newcomers’ genes began to dominate. Archaeology research in Leiden into burial mounds in the Veluwe and Utrechtse Heuvelrug areas of the Netherlands yielded this spectacular conclusion.…

Archaeologist Bjørn Peare Barthold suspected farmers in a doctorless 19th century Dutch village may have been self-medicating to manage pain and disease. By examining the skeletons' dental calculus this hypothesis could be tested. Science Magazine interviewed him about this new technique.

Immunologist Leender Trouw specialises in the complement system, which is part of the immune system. In some diseases drugs help activate or inhibit this system. This is best done ‘in the right place at the right time’ − the title of his inaugural lecture.

Sometimes an idea seems so logical and elegant at first glance, that you later wonder why no one thought of it before. Two researchers from LACDR have teamed up to develop a completely synthetic alternative to antibodies—one that mimics their size, shape and function, but which is cheaper, more stable,…

In addition to cholesterol and high blood pressure as risk factors for atherosclerosis, we may need to address our own immune system to prevent a heart attack or stroke. Marie Depuydt revealed which cells exactly reside in the atherosclerotic plaque that narrows an artery. The presence of a diverse…

A breakthrough from the PhD research of medical chemist Elmer Maurits may help patients with autoimmune diseases and blood cancer in the future. But bringing a discovery from the lab to the clinic is not so easily done. Thanks to NWO's Venture Challenge, Maurits and his team will receive ten weeks of…

In dermatology, there should be a high level of multidisciplinary collaboration among institutes and specialists, Professor of Translational Dermatology, Robert Rissmann, will say in his inaugural lecture on 8 July. He is building an infrastructure that will put pre-clinical and clinical skin research…

Two Leiden researchers have been awarded ERC Proof of Concept grants. These grants, each worth EUR 150,000, will help the grantees in their efforts to bridge the gap from basic science to real-life applications

The AtheroNeth consortium received €6 million from the Dutch Heart Foundation to gain a better understanding of the differences in disease progression among patients with atherosclerosis. The ultimate goal is to enable personalised treatment.